Ocusphere Therapeutics Inc
Hayward
About Ocusphere Therapeutics Inc
Ocusphere Therapeutics is a gene therapy startup dedicated to developing an AI-powered, modular platform to create affordable, non-viral genetic medicines for inherited retinal diseases and neurodegenerative conditions. Backed by $1.2M in funding from our co-founder and angel investor, Mr. Huang, we aim to make life-changing gene therapies accessible to patients worldwide. Leveraging cutting-edge technology from the Institute of Ophthalmology at University College London, we are committed to disrupting the high-cost gene therapy market and addressing the financial barriers many patients face.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $400.0K
- Funding stage: Seed
- Last round: Pre-Seed (Feb 2024)
- Website: ocusphere.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Genetics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/ocusphere-therapeutics-inc-127027 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.